PCRX
Pacira BioSciences, Inc.
NASDAQ: PCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$22.74
-1.77% today
Updated 2026-05-11
Market cap
$910.90M
P/E ratio
178.08
P/S ratio
1.24x
EPS (TTM)
$0.13
Dividend yield
—
52W range
$19 – $28
Volume
0.7M
Pacira BioSciences, Inc. (PCRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.70%
Operating margin
2.61%
ROE
0.71%
ROA
1.35%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2008 | $13.93M | $-41.86M | -25.41% | -325.77% | -300.62% |
| 2009 | $15.01M | $-31.71M | 18.03% | -190.24% | -211.30% |
| 2010 | $14.56M | $-27.15M | 15.70% | -153.63% | -186.44% |
| 2011 | $15.69M | $-43.33M | -6.69% | -249.23% | -276.17% |
| 2012 | $39.08M | $-52.28M | 17.77% | -126.13% | -133.77% |
| 2013 | $85.55M | $-63.91M | 35.98% | -62.29% | -74.70% |
| 2014 | $197.67M | $-13.72M | 60.82% | -2.61% | -6.94% |
| 2015 | $249.00M | $1.86M | 71.15% | 3.80% | 0.75% |
| 2016 | $276.37M | $-37.95M | 60.16% | -11.59% | -13.73% |
| 2017 | $286.63M | $-42.61M | 69.33% | -8.70% | -14.87% |
| 2018 | $337.28M | $-471000.00 | 74.25% | 4.72% | -0.14% |
| 2019 | $421.03M | $-11.02M | 74.65% | 2.49% | -2.62% |
| 2020 | $429.65M | $145.52M | 72.69% | 10.79% | 33.87% |
| 2021 | $541.53M | $41.98M | 74.10% | 16.61% | 7.75% |
| 2022 | $666.82M | $15.91M | 70.11% | 9.00% | 2.39% |
| 2023 | $674.98M | $41.95M | 72.64% | 12.99% | 6.22% |
| 2024 | $700.97M | $-99.56M | 75.69% | -10.47% | -14.20% |
| 2025 | $726.41M | $7.03M | 79.39% | 4.58% | 0.97% |